check_circleStudy Completed

Constipation

CL2012-13-Evaluation of Oral Tolerance MiraLAX Solution

Trial purpose

The purpose of this study is to compare the safety and tolerability of oral ingestion of polyethylene glycol (PEG 3350) solution concentrate to oral ingestion of a placebo solution concentrate, in participants with constipation.

Key Participants Requirements

Sex

Both

Age

18 - 75 Years

Trial summary

Enrollment Goal
65
Trial Dates
June 2013 - October 2013
Phase
Phase 2
Could I Receive a placebo
Yes
Products
Transipeg (Macrogol, BAY81-8430)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Madison, 53704, United States

Primary Outcome

  • Number of Participants With Inflammation of the Oral Mucosa
    date_rangeTime Frame:
    Visit 2 (Day 1) and Visit 3 (Day 17 ± 2 days), up to 19 days after start of treatment
    enhanced_encryption
    Safety Issue:
    Yes
  • Number of Participants With Inflammation of the Esophageal Mucosa
    date_rangeTime Frame:
    Visit 2 (Day 1) and Visit 3 (Day 17 ± 2 days), up to 19 days after start of treatment
    enhanced_encryption
    Safety Issue:
    Yes

Trial design

Evaluation of oral tolerance MiraLAX solution concentrate in subjects with chronic constipation.
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Randomized
Blinding
Single Blind
Assignment
Parallel Assignment
Trial Arms
2